Results 51 to 60 of about 4,368 (233)

A long-acting GH receptor antagonist through fusion to GH binding protein. [PDF]

, 2016
Acromegaly is a human disease of growth hormone (GH) excess with considerable morbidity and increased mortality. Somatostatin analogues are first line medical treatment but the disease remains uncontrolled in up to 40% of patients.
Artymiuk, P.J., Pradhananga, S.L., Ross, R.J., Sayers, J.R., Speak, R., Wilkinson, I.R.   +5 more
core   +1 more source

Body Composition Changes with Long-term Pegvisomant Therapy of Acromegaly

Journal of the Endocrine Society, 2021
Context In active acromegaly, the lipolytic and insulin antagonistic effects of growth hormone (GH) excess alter adipose tissue (AT) deposition, reduce body fat, and increase insulin resistance. This pattern reverses with surgical therapy.
Adriana P Kuker, W. Shen, Zhezhen Jin, Simran Singh, Jun Chen, J. Bruce, P. Freda   +6 more
semanticscholar   +1 more source

Hypertension in Acromegaly in Relationship to Biochemical Control and Mortality: Global ACROSTUDY Outcomes

Frontiers in Endocrinology, 2020
ContextHypertension is a major cardiovascular risk factor related to increased mortality in acromegaly. Surgical cure of acromegaly is associated with improvement in blood pressure levels, however little is known about the effect of pegvisomant (PEGV ...
Greisa Vila, Anton Luger, Aart Jan van der Lely, Sebastian J. C. M. M. Neggers, Susan M. Webb, Beverly M. K. Biller, Srinivas Valluri, Judith Hey-Hadavi   +7 more
doaj   +1 more source

Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant

Endocrine, 2021
Disorders of glucose metabolism are a serious acromegaly comorbidity and may be differently impacted by medical treatments of acromegaly. In this retrospective longitudinal multicenter study, we investigated the outcome of glucose metabolism and its ...
S. Chiloiro, A. Giampietro, F. Visconti, Laura Rossi, F. Donfrancesco, Cara M. Fleseriu, F. Mirra, A. Pontecorvi, A. Giustina, M. Fleseriu, L. De Marinis, A. Bianchi   +11 more
semanticscholar   +1 more source

Management of persistent acromegaly following primary therapy: The current landscape in the UK

Endocrinology, Diabetes & Metabolism, 2020
Acromegaly is the clinical consequence of chronic exposure of the tissues to excess GH and IGF‐I. It is almost exclusively the result of a GH‐secreting pituitary adenoma.
Nikolaos Kyriakakis, Khyatisha Seejore, Ahmed Hanafy, Robert D. Murray   +3 more
doaj   +1 more source

Ghrelin drives GH secretion during fasting in man [PDF]

, 2002
OBJECTIVES: In humans, fasting leads to elevated serum GH concentrations. Traditionally, changes in hypothalamic GH-releasing hormone and somatostatin release are considered as the main mechanisms that induce this elevated GH ...
Bidlingmaier, M. (Martin), Ghigo, E. (Ezio), Hofland, L.J. (Leo), Janssen, J.A.M.J.L. (Joop), Koetsveld, P.M. (Peter) van, Lamberts, S.W.J. (Steven), Lely, A-J. (Aart-Jan) van der, Muller, A.F. (Alex), Strasburger, C.J.   +8 more
core   +1 more source

Amino acid substitutions in human growth hormone affect secondary structure and receptor binding.

PLoS ONE, 2023
The interaction between human Growth Hormone (hGH) and hGH Receptor (hGHR) has basic relevance to cancer and growth disorders, and hGH is the scaffold for Pegvisomant, an anti-acromegaly therapeutic.
Andrei Rajkovic, Sandesh Kanchugal, Eldar Abdurakhmanov, Rebecca Howard, Sebastian Wärmländer, Joseph Erwin, Hugo A Barrera Saldaña, Astrid Gräslund, Helena Danielson, Samuel Coulbourn Flores   +9 more
doaj   +3 more sources

Predictors and rates of treatment-resistant tumor growth in acromegaly [PDF]

, 2005
Background: Multimodal therapy for acromegaly affords adequate disease control for many patients; however, there remains a subset of individuals that exhibit treatment-resistant disease.
Besser, G. M., Burman, P., Daly, Adrian
core   +1 more source

Acromegaly: Beyond surgery

Indian Journal of Endocrinology and Metabolism, 2013
Acromegaly is characterized by chronic, excess secretion of growth hormone (GH) from a pituitary adenoma, and elevated hepatic insulin-like growth factor 1 (IGF-1) levels.
Gaya Thanabalasingham, Ashley B Grossman
doaj   +1 more source

Acromegaly: pathogenesis & treatment [PDF]

, 2019
Acromegaly is a multi-system disorder whose etiology is most often traced back to a growth hormone-secreting pituitary adenoma (PA). Growth hormone (GH) secretion promotes insulin-like growth factor 1 (IGF-1) release from peripheral tissues, leading to ...
Tilvawala, Megha
core